Lipanor

Ciprofibrate, the active ingredient in Lipanor, is a fibrate presented as an oral tablet for oral administration. It acts on lipid metabolism to lower high triglyceride concentrations and to correct mixed dyslipidemia, helping to reduce cardiovascular risk in adult patients with these lipid disorders. The medication is prescribed by qualified healthcare professionals as part of a comprehensive lipid‑lowering strategy that includes diet and lifestyle modifications.

GNH USA supplies Lipanor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Ciprofibrate is used to manage disorders of lipid metabolism, particularly conditions characterized by elevated triglycerides. - Hypertriglyceridemia: reduces serum triglyceride levels and associated cardiovascular risk. - Mixed dyslipidemia: improves the overall lipid profile by lowering triglycerides and modestly raising HDL‑cholesterol. - Secondary hyperlipidemia: assists in controlling triglyceride elevations secondary to other metabolic conditions.

Ciprofibrate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Myalgia: muscle aches without significant weakness. - Elevated liver enzymes: mild increases in ALT or AST. - Skin reactions: rash or pruritus.

Serious or Rare Side Effects: - Myopathy or rhabdomyolysis: severe muscle breakdown, especially when combined with statins. - Hepatotoxicity: significant liver injury indicated by marked enzyme elevations. - Gallstone formation: increased risk of biliary sludge or cholelithiasis. - Severe allergic reactions: anaphylaxis or angioedema.

Before initiating therapy with Ciprofibrate, consider the following precautions. - Liver function monitoring: assess baseline hepatic enzymes and repeat periodically. - Renal function assessment: adjust use in patients with severe renal impairment. - Drug‑induced myopathy: avoid concurrent use with high‑dose statins or other myotoxic agents. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Ciprofibrate can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Statins (especially high‑dose simvastatin or lovastatin): increased risk of myopathy and rhabdomyolysis. - Anticoagulants (e.g., warfarin): potentiation of anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Gemfibrozil: additive risk of myopathy; dose adjustment may be needed. - Oral hypoglycemic agents: possible alteration of blood glucose control. - CYP2C9 substrates (e.g., phenytoin): potential increase in plasma concentrations.